Mon, May 4, 2026
[Archive]
Volume 11, Issue 2 (May 2026)
JNFS 2026, 11(2): 187-196 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Samimi R, Rashidi Nooshabadi M, Mighani S, Farzam S A, Khadem Haghighian H. The Effect of Ellagic Acid Supplementation on Inflammatory Markers and Adiponectin Levels in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blind Clinical Trial. JNFS 2026; 11 (2) :187-196
URL: http://jnfs.ssu.ac.ir/article-1-1436-en.html
URL: http://jnfs.ssu.ac.ir/article-1-1436-en.html
Rasoul Samimi 
, Mohamadreza Rashidi Nooshabadi , Sara Mighani * , Seyed Amir Farzam , Hossein Khadem Haghighian
, Mohamadreza Rashidi Nooshabadi , Sara Mighani * , Seyed Amir Farzam , Hossein Khadem Haghighian
Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran
Abstract: (547 Views)
Background: The progression and pathogenesis of non-alcoholic fatty liver disease (NAFLD) are intimately connected to elevated oxidative stress and chronic inflammatory responses. With the antioxidant qualities of Ellagic acid (EA), this study aims to assay the impact of EA on inflammatory markers and adiponectin hormone in individuals with NAFLD. Methods: In a double-blind, controlled clinical trial, 44 people meeting the study criteria were randomly assigned to consume 180 mg of EA per day (EAG, n=22) or placebo (PG, n=22) over an 8-week period. Measurements of anthropometric indices, food intake, physical activity levels, inflammatory markers, and adiponectin were taken at both the beginning and conclusion of the trial. The results were evaluated with the help of SPSS software. Results. No meaningful statistical variations were noticed between the EA and placebo groups regarding anthropometric variables, dietary intake, or physical activity levels before and after the intervention (P>0.05). After receiving the supplement, the average changes of inflammatory agents, interleukin 6 (IL-6) (from 8.69±3.07 to 5.11±1.24 mg/dl, P=0.04), and tumor necrosis factor-alpha (TNF-α) (from 15.09±3.52 to 10.61±2.44 pg/ml, P=0.037), at the start and end of the study, were significantly reduced (P<0.05). In addition, a notable increase in the level of adiponectin was noted in the EAG group (P<0.05). Conclusions. In light of the outcomes, EA can be utilized as an effective therapeutic intervention to ameliorate complications derived from NAFLD.
Type of article: orginal article |
Subject:
public specific
Received: 2025/08/18 | Published: 2026/05/30 | ePublished: 2026/05/30
Received: 2025/08/18 | Published: 2026/05/30 | ePublished: 2026/05/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
